Answers are grounded in this paper and cite their sources.
To evaluate the impact of ublituximab on radiologic outcomes and NEDA at 12 weeks in participants with highly active disease at baseline in the phase 3 ULTIMATE I and II studies.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: